{
  "id": 10791995,
  "title": "Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results",
  "url": "https://urgent.news/2026/09/29/eli-lillys-experimental-weight-loss-drug-shows-promising-results",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-09-29T22:00:04.000Z",
  "source": {
    "name": "Time",
    "slug": "time",
    "url": "https://time.com/article/2026/09/29/eli-lilly-triple-targeting-experimental-weight-loss-drug-promising-results/"
  },
  "original_language": "en",
  "account": "Two recent studies published in the Lancet and the New England Journal of Medicine have shown promising weight-loss results from Eli Lilly's experimental drug retatrutide. In the Lancet study presented at the European Association for the Study of Diabetes, people with Type 2 diabetes who took the highest dose of retatrutide lost an average of 18.8% of their starting body weight, while those on a placebo lost only 5.1%. About a third of participants on the highest dose lost at least 25% of their body weight, compared to 3% of the placebo group over the 1.5-year study period. Dr. Juan Pablo Frias, a study author, noted that retatrutide is the most potent drug currently available, showing the greatest percent weight loss in people with Type 2 diabetes. Those taking the highest dose also experienced significant improvement in diabetes control, with 63% of participants lowering their A1C to below 6.5% and losing at least 10% of their body weight. In the New England Journal of Medicine study, people without diabetes who took the highest dose lost about 25% of their starting body weight, while 3.9% of the placebo group lost the same amount. Retatrutide targets three weight-related hormones - GLP-1, GIP, and glucagon - which may explain its more potent effects on weight loss in people with diabetes compared to drugs targeting GLP-1 alone. Side effects among retatrutide users were similar to those seen with other GLP-1 medications, including gastrointestinal issues like abdominal cramps, nausea, vomiting, and diarrhea. Eli Lilly plans to submit a request to the FDA in early 2027 to approve retatrutide based on these study results.",
  "summary": "Two new studies on the experimental drug retatrutide show it helps overweight people lose weight, whether or not they have diabetes.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}